BR112022021879A2 - Conjugados de decorina guiados por peptídeos de homing para uso no tratamento de epidermólise bolhosa - Google Patents

Conjugados de decorina guiados por peptídeos de homing para uso no tratamento de epidermólise bolhosa

Info

Publication number
BR112022021879A2
BR112022021879A2 BR112022021879A BR112022021879A BR112022021879A2 BR 112022021879 A2 BR112022021879 A2 BR 112022021879A2 BR 112022021879 A BR112022021879 A BR 112022021879A BR 112022021879 A BR112022021879 A BR 112022021879A BR 112022021879 A2 BR112022021879 A2 BR 112022021879A2
Authority
BR
Brazil
Prior art keywords
treatment
decorin
guided
epidermolysis bullosa
conjugates
Prior art date
Application number
BR112022021879A
Other languages
English (en)
Portuguese (pt)
Inventor
Järvinen Tero
Pemmari Toini
May Ulrike
Original Assignee
Tampere Univ Foundation Sr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tampere Univ Foundation Sr filed Critical Tampere Univ Foundation Sr
Publication of BR112022021879A2 publication Critical patent/BR112022021879A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725Proteoglycans, e.g. aggreccan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112022021879A 2020-04-28 2021-04-28 Conjugados de decorina guiados por peptídeos de homing para uso no tratamento de epidermólise bolhosa BR112022021879A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016359P 2020-04-28 2020-04-28
FI20205431 2020-04-28
PCT/FI2021/050318 WO2021219940A1 (en) 2020-04-28 2021-04-28 Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa

Publications (1)

Publication Number Publication Date
BR112022021879A2 true BR112022021879A2 (pt) 2022-12-20

Family

ID=75870661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021879A BR112022021879A2 (pt) 2020-04-28 2021-04-28 Conjugados de decorina guiados por peptídeos de homing para uso no tratamento de epidermólise bolhosa

Country Status (10)

Country Link
US (1) US20230167162A1 (https=)
EP (1) EP4142771A1 (https=)
JP (1) JP7824885B2 (https=)
KR (1) KR20230005314A (https=)
CN (1) CN115605218B (https=)
AU (1) AU2021266157A1 (https=)
BR (1) BR112022021879A2 (https=)
CA (1) CA3180694A1 (https=)
IL (1) IL297703A (https=)
WO (1) WO2021219940A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118001404B (zh) * 2024-02-06 2025-02-25 四川大学华西医院 抑制C17orf67基因表达试剂在制备治疗获得性大疱表皮松解症药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors

Also Published As

Publication number Publication date
CN115605218A (zh) 2023-01-13
CA3180694A1 (en) 2021-11-04
JP2023523719A (ja) 2023-06-07
WO2021219940A1 (en) 2021-11-04
AU2021266157A1 (en) 2022-12-08
CN115605218B (zh) 2026-03-24
JP7824885B2 (ja) 2026-03-05
EP4142771A1 (en) 2023-03-08
IL297703A (en) 2022-12-01
US20230167162A1 (en) 2023-06-01
KR20230005314A (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
PH12019502278A1 (en) Conjugation of a cytotoxic drug with bis-linkage
MX2021004069A (es) Enlazadores de conjugacion que contienen el grupo 2,3-diaminosuccinilo.
BR112022002599A2 (pt) Vesícula extracelular ligada a moléculas e usos da mesma
EP3949969A3 (en) Benzazepine compounds, conjugates, and uses thereof
MX2023001466A (es) Enlazadores de base peptidica.
MX2020006192A (es) Un conjugado de un analogo de tubulisina con enlazadores ramificados.
BR112016024363A2 (pt) conjugado de anticorpo-fármaco e seu uso para tratamento de câncer
CO2023016246A2 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y sus usos
MX2022000037A (es) Enlazadores hidrofilicos para conjugados de peptidos multivalentes.
MX2022003268A (es) Liberacion selectiva de farmaco a partir de conjugados internalizados de compuestos biologicamente activos.
PE20161209A1 (es) Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
EA202192137A1 (ru) Конъюгат аматоксинового аналога с разветвленными линкерами
GEAP202316334A (en) Nanoemulsion adjuvant composition for pneumococcal conjugate vaccines
BR112022002720A2 (pt) Formulações de conjugados de benzazepinas e usos das mesmas
BR112022005026A2 (pt) Conjugados terapêuticos
AR052541A1 (es) Vacunas de glicoconjugados que contiene peptidoglicina
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
BRPI0519583A2 (pt) composiÇço cosmÉtica apropriada para relaxar rugas de expressço, e, mÉtodo para tratamento cosmÉtico para relaxamento de rugas
BRPI0513145A (pt) conjugados de amino, aminoácido ou peptìdeo de ácido retinóico
BR112022021879A2 (pt) Conjugados de decorina guiados por peptídeos de homing para uso no tratamento de epidermólise bolhosa
BR112022024691A2 (pt) Conjugados anticorpo biespecífico - fármaco direcionados a egfr e muc1 e usos dos mesmos
WO2021211683A3 (en) Compositions and methods for targeted therapeutic delivery to bone
BR112022013255A2 (pt) Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
MX2023015471A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos humanizados que eligen como blanco la proteina asociada al receptor activador de plasminogeno tipo uroquinasa (uparap).